Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 9/2009

01.09.2009 | Focussed Research Review

HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank

verfasst von: Rosa Mendez, Natalia Aptsiauri, Ana Del Campo, Isabel Maleno, Teresa Cabrera, Francisco Ruiz-Cabello, Federico Garrido, Angel Garcia-Lora

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Altered HLA class I and class II cell surface expression has been reported in many types of malignancy and represents one of the major mechanism by which tumour cells escape from T lymphocytes. In this report, we review the results obtained from the study of constitutive and IFN-gamma-induced expression of HLA class I and II molecules in 91 human melanoma cell lines from the European Searchable Tumour Cell Line Database, and compare them with published data on HLA expression in other types of cancer. Various types of alterations in HLA class I cell surface expression were found in a high percentage (67%) of the studied cell lines. These alterations range from total to selective HLA class I loss and are associated with β2-microglobulin gene mutations, transcriptional downregulation of HLA class I genes and antigen processing machinery components, or with the loss of heterozygosity in chromosome 6. The most frequently observed phenotype is selective downregulation of HLA-B locus, reversible after treatment with IFN-gamma. The expression of constitutive- or IFN-gamma induced-surface expression of at least one HLA class II locus is positive in 71.5% of the analysed cell lines. Four different HLA class II expression phenotypes were defined, and a positive correlation between the expression of class I and II molecules is discussed. More detailed information on the HLA expression patterns and others immunological characteristics of these melanoma cell lines can be found on the following website http://​www.​ebi.​ac.​uk/​ipd/​estdab.
Literatur
1.
Zurück zum Zitat Altomonte M, Fonsatti E, Visintin A, Maio M (2003) Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22:6564–6569PubMedCrossRef Altomonte M, Fonsatti E, Visintin A, Maio M (2003) Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 22:6564–6569PubMedCrossRef
2.
Zurück zum Zitat Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405–6411PubMedCrossRef Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S (2006) Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res 66:6405–6411PubMedCrossRef
3.
Zurück zum Zitat Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727–1733PubMedCrossRef Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727–1733PubMedCrossRef
4.
Zurück zum Zitat Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529PubMedCrossRef Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529PubMedCrossRef
5.
Zurück zum Zitat Brady MS, Lee F, Petrie H, Eckels DD, Lee JS (2000) CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 48:621–626PubMedCrossRef Brady MS, Lee F, Petrie H, Eckels DD, Lee JS (2000) CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 48:621–626PubMedCrossRef
6.
Zurück zum Zitat Cabrera T, Ruiz-Cabello F, Garrido F (1995) Biological implications of HLA-DR expression in tumours. Scand J Immunol 41:398–406PubMedCrossRef Cabrera T, Ruiz-Cabello F, Garrido F (1995) Biological implications of HLA-DR expression in tumours. Scand J Immunol 41:398–406PubMedCrossRef
7.
Zurück zum Zitat Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50:127–134PubMedCrossRef Cabrera T, Angustias Fernandez M, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F (1996) High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50:127–134PubMedCrossRef
8.
Zurück zum Zitat Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination. Cancer Immunol Immunother 56:709–717PubMedCrossRef Cabrera T, Lara E, Romero JM, Maleno I, Real LM, Ruiz-Cabello F, Valero P, Camacho FM, Garrido F (2007) HLA class I expression in metastatic melanoma correlates with tumour development during autologous vaccination. Cancer Immunol Immunother 56:709–717PubMedCrossRef
9.
Zurück zum Zitat Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12:4163–4170PubMedCrossRef Dengjel J, Nastke MD, Gouttefangeas C, Gitsioudis G, Schoor O, Altenberend F, Müller M, Krämer B, Missiou A, Sauter M, Hennenlotter J, Wernet D, Stenzl A, Rammensee HG, Klingel K, Stevanović S (2006) Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 12:4163–4170PubMedCrossRef
10.
Zurück zum Zitat Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N (2006) Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 177:3100–3107PubMed Derré L, Corvaisier M, Charreau B, Moreau A, Godefroy E, Moreau-Aubry A, Jotereau F, Gervois N (2006) Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 177:3100–3107PubMed
11.
Zurück zum Zitat Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumour immune escape. J Cell Physiol 195:346–355PubMedCrossRef Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumour immune escape. J Cell Physiol 195:346–355PubMedCrossRef
12.
Zurück zum Zitat Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491–499PubMedCrossRef Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 14:491–499PubMedCrossRef
13.
Zurück zum Zitat Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95PubMedCrossRef Garrido F, Ruiz-Cabello F, Cabrera T, Pérez-Villar JJ, López-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95PubMedCrossRef
14.
Zurück zum Zitat Garrido F, Cabrera T, Acolla RS, Bensa JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades Crh, Salvaneschi L, Stern PL, Ziegler A (1997) HLA and cancer: 12th international histocompatibility workshop study. In: Charron D (ed) HLA, genetic diversity of HLA. Functional and medical implications, vol 1. EDK, p 445 Garrido F, Cabrera T, Acolla RS, Bensa JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades Crh, Salvaneschi L, Stern PL, Ziegler A (1997) HLA and cancer: 12th international histocompatibility workshop study. In: Charron D (ed) HLA, genetic diversity of HLA. Functional and medical implications, vol 1. EDK, p 445
15.
Zurück zum Zitat Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158PubMedCrossRef Garrido F, Algarra I (2001) MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117–158PubMedCrossRef
16.
Zurück zum Zitat Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, Bander NH (1996) Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 155:361–367PubMedCrossRef Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, Bander NH (1996) Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 155:361–367PubMedCrossRef
17.
Zurück zum Zitat Ibrahim EC, Allory Y, Commo F, Gattegno B, Callard P, Paul P (2003) Altered pattern of major histocompatibility complex expression in renal carcinoma: tumour-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am J Pathol 162:501–508PubMed Ibrahim EC, Allory Y, Commo F, Gattegno B, Callard P, Paul P (2003) Altered pattern of major histocompatibility complex expression in renal carcinoma: tumour-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma. Am J Pathol 162:501–508PubMed
18.
Zurück zum Zitat Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154:745–754PubMed Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S (1999) Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 154:745–754PubMed
19.
Zurück zum Zitat Kageshita T, Ishihara T, Campoli M, Ferrone S (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65:419–428PubMedCrossRef Kageshita T, Ishihara T, Campoli M, Ferrone S (2005) Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65:419–428PubMedCrossRef
20.
21.
Zurück zum Zitat Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E (2007) Recognition of prostate and melanoma tumour cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 67:5498–5504PubMedCrossRef Kobayashi H, Nagato T, Sato K, Aoki N, Kimura S, Murakami M, Iizuka H, Azumi M, Kakizaki H, Tateno M, Celis E (2007) Recognition of prostate and melanoma tumour cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 67:5498–5504PubMedCrossRef
22.
Zurück zum Zitat Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961–976PubMedCrossRef Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ (2000) Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 191:961–976PubMedCrossRef
23.
Zurück zum Zitat Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF (2007) A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumour cells to CD4+ T lymphocytes. Cancer Immunol Immunother 56:1565–1575PubMedCrossRef Larrieu P, Ouisse LH, Guilloux Y, Jotereau F, Fonteneau JF (2007) A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumour cells to CD4+ T lymphocytes. Cancer Immunol Immunother 56:1565–1575PubMedCrossRef
24.
Zurück zum Zitat LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W (2004) Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34:1513–1525PubMedCrossRef LeibundGut-Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A, Acha-Orbea H, Reith W (2004) Mini-review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol 34:1513–1525PubMedCrossRef
25.
Zurück zum Zitat Li P, Gregg JL, Wang N, Zhou D, O’Donnell P, Blum JS, Crotzer VL (2005) Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol Rev 207:206–217PubMedCrossRef Li P, Gregg JL, Wang N, Zhou D, O’Donnell P, Blum JS, Crotzer VL (2005) Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol Rev 207:206–217PubMedCrossRef
26.
Zurück zum Zitat Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2003) Identification of a colorectal tumour-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 63:6735–6743PubMed Maccalli C, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2003) Identification of a colorectal tumour-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 63:6735–6743PubMed
27.
Zurück zum Zitat Mach B, Steimle V, Martinez-Soria E, Reith W (1996) Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 14:301–331PubMedCrossRef Mach B, Steimle V, Martinez-Soria E, Reith W (1996) Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 14:301–331PubMedCrossRef
28.
Zurück zum Zitat Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51:389–396PubMedCrossRef Maleno I, López-Nevot MA, Cabrera T, Salinero J, Garrido F (2002) Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51:389–396PubMedCrossRef
29.
Zurück zum Zitat Maleno I, Cabrera CM, Cabrera T, Paco L, López-Nevot MA, Collado A, Ferrón A, Garrido F (2004) Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253PubMedCrossRef Maleno I, Cabrera CM, Cabrera T, Paco L, López-Nevot MA, Collado A, Ferrón A, Garrido F (2004) Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253PubMedCrossRef
30.
Zurück zum Zitat Maleno I, Romero JM, Cabrera T, Paco L, Aptsiauri N, Cozar JM, Tallada M, López-Nevot MA, Garrido F (2006) LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 58:503–510PubMedCrossRef Maleno I, Romero JM, Cabrera T, Paco L, Aptsiauri N, Cozar JM, Tallada M, López-Nevot MA, Garrido F (2006) LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 58:503–510PubMedCrossRef
31.
Zurück zum Zitat Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM (2005) One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol 174:1751–1759PubMed Mandic M, Castelli F, Janjic B, Almunia C, Andrade P, Gillet D, Brusic V, Kirkwood JM, Maillere B, Zarour HM (2005) One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma. J Immunol 174:1751–1759PubMed
32.
Zurück zum Zitat Marín R, Ruiz-Cabello F, Pedrinaci S, Méndez R, Jiménez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumours. Immunogenetics 54:767–775PubMed Marín R, Ruiz-Cabello F, Pedrinaci S, Méndez R, Jiménez P, Geraghty DE, Garrido F (2003) Analysis of HLA-E expression in human tumours. Immunogenetics 54:767–775PubMed
33.
Zurück zum Zitat Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273PubMedCrossRef Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273PubMedCrossRef
34.
Zurück zum Zitat Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T (2006) Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci 97:57–63PubMedCrossRef Matsushita K, Takenouchi T, Shimada H, Tomonaga T, Hayashi H, Shioya A, Komatsu A, Matsubara H, Ochiai T (2006) Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: possible involvement of c-myc suppression by interferon-gamma in situ. Cancer Sci 97:57–63PubMedCrossRef
35.
Zurück zum Zitat Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197–206PubMedCrossRef Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ (2008) Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57:197–206PubMedCrossRef
36.
Zurück zum Zitat Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11:2552–2560PubMedCrossRef Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11:2552–2560PubMedCrossRef
37.
Zurück zum Zitat Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jiménez P, Pedrinaci S, Pawelec G, Ruiz-Cabello F, Garrido F (2008) Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 57:719–729PubMedCrossRef Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jiménez P, Pedrinaci S, Pawelec G, Ruiz-Cabello F, Garrido F (2008) Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 57:719–729PubMedCrossRef
38.
Zurück zum Zitat Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H (2008) Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 99:1462–1467PubMedCrossRef Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H (2008) Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer 99:1462–1467PubMedCrossRef
39.
Zurück zum Zitat Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U (2003) Natural T cell immunity against cancer. Clin Cancer Res 9:4296–4303PubMed Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U (2003) Natural T cell immunity against cancer. Clin Cancer Res 9:4296–4303PubMed
40.
Zurück zum Zitat Novellino L, Castelli C, Parmiani G (2005) A listing of human tumour antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207PubMedCrossRef Novellino L, Castelli C, Parmiani G (2005) A listing of human tumour antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54:187–207PubMedCrossRef
41.
Zurück zum Zitat Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D (2005) Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice. Clin Cancer Res 11:5241–5247PubMedCrossRef Paschen A, Song M, Osen W, Nguyen XD, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D (2005) Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice. Clin Cancer Res 11:5241–5247PubMedCrossRef
42.
Zurück zum Zitat Pawelec G, Marsh S (2006) ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 55:623–627PubMedCrossRef Pawelec G, Marsh S (2006) ESTDAB: a collection of immunologically characterised melanoma cell lines and searchable databank. Cancer Immunol Immunother 55:623–627PubMedCrossRef
43.
Zurück zum Zitat Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F (2000) Molecular strategies to define HLA haplotype loss in microdissected tumour cells. Hum Immunol 61:1001–1012PubMedCrossRef Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F (2000) Molecular strategies to define HLA haplotype loss in microdissected tumour cells. Hum Immunol 61:1001–1012PubMedCrossRef
44.
Zurück zum Zitat Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F (1999) Expression of HLA G in human tumors is not a frequent event. Int J Cancer 81(4):512–518PubMedCrossRef Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F (1999) Expression of HLA G in human tumors is not a frequent event. Int J Cancer 81(4):512–518PubMedCrossRef
45.
Zurück zum Zitat Reith W, LeibundGut-Landmann S, Waldburger JM (2005) Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5:793–806PubMedCrossRef Reith W, LeibundGut-Landmann S, Waldburger JM (2005) Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5:793–806PubMedCrossRef
46.
Zurück zum Zitat Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumour immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103:4251–4258PubMedCrossRef Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, Weisenberger DD, Chan WC, Muller-Hermelink HK, Jaffe ES, Gascoyne RD, Campo E, Fuchs DA, Spier CM, Fisher RI, Delabie J, Rosenwald A, Staudt LM, Grogan TM (2004) Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumour immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103:4251–4258PubMedCrossRef
47.
Zurück zum Zitat Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA (2002) Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumour-infiltrating lymphocytes from a patient with melanoma. J Immunol 169:6036–6047PubMed Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA (2002) Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumour-infiltrating lymphocytes from a patient with melanoma. J Immunol 169:6036–6047PubMed
48.
Zurück zum Zitat Rodríguez T, Méndez R, Del Campo A, Jiménez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34PubMedCrossRef Rodríguez T, Méndez R, Del Campo A, Jiménez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34PubMedCrossRef
49.
Zurück zum Zitat Rodríguez T, Méndez R, Del Campo A, Aptsiauri N, Martín J, Orozco G, Pawelec G, Schadendorf D, Ruiz-Cabello F, Garrido F (2007) Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 59:123–133PubMedCrossRef Rodríguez T, Méndez R, Del Campo A, Aptsiauri N, Martín J, Orozco G, Pawelec G, Schadendorf D, Ruiz-Cabello F, Garrido F (2007) Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics 59:123–133PubMedCrossRef
50.
Zurück zum Zitat Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H (2005) A novel strategy for the discovery of MHC class II-restricted tumour antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 65:10068–10078PubMedCrossRef Röhn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H (2005) A novel strategy for the discovery of MHC class II-restricted tumour antigens: identification of a melanotransferrin helper T-cell epitope. Cancer Res 65:10068–10078PubMedCrossRef
51.
Zurück zum Zitat Rolland P, Deen S, Scott I, Durrant L, Spendlove I (2007) Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13:3591–3596PubMedCrossRef Rolland P, Deen S, Scott I, Durrant L, Spendlove I (2007) Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer. Clin Cancer Res 13:3591–3596PubMedCrossRef
52.
Zurück zum Zitat Sabapathy K, Nam SY (2008) Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function. Cell Death Differ 15:1364–1374PubMedCrossRef Sabapathy K, Nam SY (2008) Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function. Cell Death Differ 15:1364–1374PubMedCrossRef
53.
Zurück zum Zitat Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ (2008) Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 57:601–609PubMedCrossRef Speetjens FM, de Bruin EC, Morreau H, Zeestraten EC, Putter H, van Krieken JH, van Buren MM, van Velzen M, Dekker-Ensink NG, van de Velde CJ, Kuppen PJ (2008) Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother 57:601–609PubMedCrossRef
54.
Zurück zum Zitat van den Elsen PJ, Gobin SJ, van Eggermond MC, Peijnenburg A (1998) Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 48:208–221PubMedCrossRef van den Elsen PJ, Gobin SJ, van Eggermond MC, Peijnenburg A (1998) Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 48:208–221PubMedCrossRef
55.
Zurück zum Zitat van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S (1988) Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019–1025PubMed van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S (1988) Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 48:1019–1025PubMed
56.
Zurück zum Zitat van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, Oudejans JJ (2008) Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumour infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123:609–615PubMedCrossRef van Houdt IS, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJ, Hooijberg E, van Leeuwen PA, Meijer CJ, Oudejans JJ (2008) Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumour infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123:609–615PubMedCrossRef
57.
Zurück zum Zitat Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6–10PubMedCrossRef Watson NF, Ramage JM, Madjd Z, Spendlove I, Ellis IO, Scholefield JH, Durrant LG (2006) Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int J Cancer 118:6–10PubMedCrossRef
Metadaten
Titel
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank
verfasst von
Rosa Mendez
Natalia Aptsiauri
Ana Del Campo
Isabel Maleno
Teresa Cabrera
Francisco Ruiz-Cabello
Federico Garrido
Angel Garcia-Lora
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 9/2009
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0701-z

Weitere Artikel der Ausgabe 9/2009

Cancer Immunology, Immunotherapy 9/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.